SomaLogic, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the SomaLogic, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, SomaLogic, Inc. has recorded 50 reports. The latest transaction was filed on 9 January 2024 (Disposition). Among the most active insiders: POST RICHARD A. The full history is accessible without an account.
Buys €501,710 €5,219 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 January 2024
All Executives50 Thresholds0 Prospectus0 Other0
Declarations 50 total
● Director · Executives · 5 Jan 2024
7,630 shares Common Stock SEC:0001209191-24-001310:0
● Director · Executives · 5 Jan 2024
3,430 shares Common Stock SEC:0001209191-24-001314:0
● Chief People Officer · Executives · 5 Jan 2024
17,143 shares Common Stock SEC:0001209191-24-001330:0
● General Counsel · Executives · 5 Jan 2024
21,027 shares Common Stock SEC:0001209191-24-001318:0
● Director · Executives · 5 Jan 2024
57,430 shares Common Stock SEC:0001209191-24-001328:0
● Interim CEO · Executives · 5 Jan 2024
48,425 shares Common Stock SEC:0001209191-24-001334:0
● Director · Executives · 5 Jan 2024
23,430 shares Common Stock SEC:0001209191-24-001322:0
● Director · Executives · 5 Jan 2024
3,430 shares Common Stock SEC:0001209191-24-001324:0
● Director · Executives · 5 Jan 2024
78,430 shares Common Stock SEC:0001209191-24-001316:0
◇ Chief People Officer · Executives · 9 Nov 2023
16,750 shares Common Stock SEC:0001209191-23-055204:0
▼ General Counsel · Executives · 2 Mar 2023
765 shares @ US$2.5576 100.0% of flow Common Stock SEC:0001209191-23-051188:0
◇ Chief People Officer · Executives · 13 Sept 2023
9,502 shares Common Stock SEC:0001209191-23-051193:0
▼ Interim CEO · Executives · 2 Mar 2023
1,412 shares @ US$2.5576 100.0% of flow Common Stock SEC:0001209191-23-051196:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021845:0
◆ Chief Accounting Officer · Executives · 17 Mar 2023
12,500 shares 0Common Stock SEC:0001213900-23-021843:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021847:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021839:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021841:0
◆ Chief Financial Officer · Executives · 17 Mar 2023
25,000 shares 0Common Stock SEC:0001213900-23-021840:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021846:0
◆ Director · Executives · 17 Mar 2023
3,430 shares 0Common Stock SEC:0001213900-23-021848:0
◆ Executive Chair · Executives · 17 Mar 2023
28,500 shares 0Common Stock SEC:0001213900-23-021842:0
◆ General Counsel · Executives · 17 Mar 2023
25,000 shares 0Common Stock SEC:0001213900-23-021844:0
◆ Director · Executives · 29 Sept 2022
215,193 shares Class A Common Stock SEC:0000919574-22-007074:0
◆ Chief Accounting Officer · Executives · 13 Sept 2022
60,011 shares 0Common Stock SEC:0001213900-22-056950:0
25 of 50 declarations
Load more (25 remaining) 关于 SomaLogic, Inc. SomaLogic, Inc. 是一家总部位于美国、专注于大规模测量蛋白质以改善生物学理解、生物标志物发现和疾病研究的蛋白质组学公司。该公司以其 SOMAmer® 化学和 SomaScan® 平台而闻名,这些技术旨在从极小的样本量中分析数千种蛋白质。实际上,SomaLogic 将自己定位在发现研究、转化科学和基于实验室的蛋白质组学服务的交汇点,其商业模式结合了技术访问、数据服务和实验室检测能力。它还运营着一个 CLIA 认证、CAP 认可的实验室,并支持一个全球 SomaLogic 授权站点网络。([somalogic.com](https://somalogic.com/company-overview/?utm_source=openai))
该公司总部位于美国科罗拉多州博尔德,运营地址为 2945 Wilderness Pl., Boulder, CO 80301。SomaLogic 还建立了有意义的知识产权基础,包括与其 SOMAmer 试剂和多重蛋白质组学平台相关的已授权专利和待批申请。这一知识产权地位一直是其差异化的核心,尤其是在竞争激烈的蛋白质组学市场中,检测深度、重现性、灵敏度和样本效率是投资者关注的关键点。([somalogic.com](https://somalogic.com/company-overview/?utm_source=openai))
在商业方面,SomaLogic 服务于制药和生物技术公司、学术研究机构、政府研究人员以及合同研究组织。其主要业务线包括按服务付费的蛋白质组学、SomaScan 检测服务、数据咨询服务、SomaScan 面板和 SomaSignal 检测。其价值主张很简单:从最少的样本输入中提供广泛的蛋白质覆盖,从而在多个治疗领域的生物标志物发现、临床试验监测和通路分析中实现更快的工作。([somalogic.com](https://somalogic.com/?utm_source=openai))
从竞争角度来看,SomaLogic 在精准医疗和多组学领域的一个专业但具有战略重要性的细分市场中运营。该公司强调大规模蛋白质覆盖、分析精度和重现性,并指出其广泛的出版记录和大型蛋白质组学数据集是技术吸引力的证据。在地理上,其运营基地在美国,而其商业范围通过授权站点和服务合作伙伴遍及全球。([somalogic.com](https://somalogic.com/?utm_source=openai))
最近最重要的进展是战略性的而非纯粹运营性的:Illumina 宣布并完成了对 SomaLogic 的收购,并于 2026 年 1 月 30 日完成交割。该交易将 SomaLogic 的蛋白质组学平台整合到一个更大的多组学生态系统中,对于关注美国 NYSE/NASDAQ 综合体上市的 SLGCW 的投资者而言,这应被视为近期决定性事件。它可能会改善分销和战略相关性,但也意味着股权故事现在必须通过所有权变更和收购后整合的视角来解读。([illumina.com](https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b7bf54f5-b534-47b4-a629-02ade3b10178&utm_source=openai))